2024-11-12T11:38:30-06:00 2023-12-31 946214841 ARMANINO ADVISORY LLC 2700 CAMINO RAMON STE 350 SAN RAMON CA 945835004 990 2023-01-01 204284925 QUANTUM LEAP HEALTHCARE COLLABORATIVE QUAN 8558660505 499 ILLINOIS AVE 200 SAN FRANCISCO CA 94158 JAMES PALAZZOLO CEO 8558660505 2024-11-04 1 1 MATTHEW PETROSKI P00853132 9257902600 2024-11-04 2023 2024-10-15 13:58:12Z JAMES PALAZZOLO 499 ILLINOIS AVE 200 SAN FRANCISCO CA 94158 99901597 0 X WWW.QUANTUMLEAPHEALTH.ORG X 2005 CA THE MISSION OF QUANTUM LEAP HEALTHCARE COLLARBORATIVE IS TO PROVIDE (CONTINUED ON SCH. O)MANAGEMENT AND FINANCIAL SUPPORT TO HEALTHCARE RESEARCH ORGANIZATIONS, PARTICULARLY INVOLVING BREAST CANCER RESEARCH AND TREATMENT. 12 11 121 25 0 0 18937275 1389552 27865728 42063571 450842 1694776 0 0 47253845 45147899 0 0 0 0 16155579 19595045 0 0 460963 31084816 28164397 47240395 47759442 13450 -2611543 60913948 58201960 30870765 29374723 30043183 28827237 X THE MISSION OF QUANTUM LEAP HEALTHCARE COLLARBORATIVE IS TO PROVIDE MANAGEMENT AND FINANCIAL SUPPORT TO HEALTHCARE RESEARCH ORGANIZATIONS, PARTICULARLY INVOLVING BREAST CANCER RESEARCH AND TREATMENT. 0 0 36213899 40785731 I-SPY TRIALS: QUANTUM LEAP SPONSORS THE I-SPY TRIALS (INVESTIGATION OF SERIAL STUDIES TO PREDICT YOUR THERAPEUTIC RESPONSE WITH IMAGING AND MOLECULAR ANALYSIS). I-SPY HAS BEEN RE-ENGINEERING THE APPROACH TO CLINICAL TRIALS, WITH A GOAL OF GETTING THE RIGHT DRUG TO THE RIGHT PATIENT AT THE TIME WHEN THEY WILL BENEFIT MOST, AND TO ACHIEVE THIS FASTER THAN POSSIBLE IN PREVIOUS TRIAL MODELS. ADDITIONALLY, I-SPY AIMS TO SIGNIFICANTLY REDUCE THE OVERALL COST, TIME, AND NUMBER OF PATIENTS REQUIRED TO BRING NEW DRUGS TO MARKET. THE I-SPY TRIAL PROGRAM INTEGRATES AND LINKS PHASE I (I-SPY PHASE 1), PHASE II (I-SPY 2), AND FUTURE PHASES TO BUILD A PIPELINE OF NOVEL AGENTS AND ACCELERATE THE PROCESS OF IDENTIFYING THE SUBSET OF HIGH-RISK BREAST CANCER PATIENTS THAT WILL BENEFIT FROM THESE NEW AGENTS, AND GET THESE DRUG INTO THE CLINIC IN A TIMELY MANNER. 5395073 1136560 THE COVID/ARDS STUDY TRIAL FOCUSED ON PATIENTS WHOSE REACTIONS TO THE VIRUS MAKE THEM CRITICALLY ILL AND, IN MANY CASES, RESULT IN DEATH. THE TRIAL'S PRIMARY FOCUS WAS TO IDENTIFY PROMISING DRUGS THAT EITHER NEUTRALIZE THE VIRUS, HELP HEAL THE LUNG DAMAGE FROM THE VIRUS (WHICH CAUSED ACUTE RESPIRATORY DISTRESS SYNDROME), OR CHANGE THE IMMUNE SYSTEM REACTION RESULTING IN ILLNESS. THE TRIAL OPENED IN JUNE 2020 AND WILL CONTINUE UNTIL A DRUG OR COMBINATIONS OF DRUGS ARE FOUND THAT PREVENT THE NECESSITY FOR VENTILATION TREATMENT AND ELIMINATE DEATH FROM THE DISEASE. IN FISCAL YEAR 2022, THE PROTOCOL WAS AMENDED TO EXPAND TO ALL ILLNESSES CONTRIBUTING TO ADULT RESPIRATORY DISTRESS SYNDROME, OR ARDS. 1330659 60300 BREAST CANCER TRIALS (BCT) - LAUNCHED IN 2008, FOLLOWING A SUCCESSFUL UCSF-NCI SPONSORED RESEARCH PILOT, ITS MISSION IS TO MAKE PATIENT CONSIDERATION OF TRIALS THE NORM VS. THE EXCEPTION. WE BELIEVE THAT ALL PATIENTS SHOULD HAVE ACCESS TO THE LATEST MEDICAL KNOWLEDGE ABOUT BREAST CANCER TREATMENT AS WELL AS THE OPPORTUNITY TO ADVANCE BREAST CANCER RESEARCH. BCT LISTS OVER 600 STUDIES FOR PEOPLE WITH NEWLY DIAGNOSED BREAST CANCER, METASTATIC DISEASE, OR POST-TREATMENT SURVIVORS. IT INCLUDES INNOVATIVE TRIALS OF TARGETED AND IMMUNOTHERAPIES AS WELL AS OBSERVATIONAL STUDIES LOOKING AT QUALITY OF LIFE, GENETIC MUTATIONS, AND BREAST CANCER SURVIVORSHIP, ACCOMPANIED BY EASY-TO-READ TRIAL SUMMARIES. 616465 80980 616465 80980 43556096 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 1 35 0 1 121 1 0 0 0 0 0 0 0 0 0 0 0 0 X 12 11 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA X X X THE ORGANIZATION 8558660505 499 ILLINOIS AVE 200 SAN FRANCISCO CA 94158 DAVE MANDELKERN MS CHAIRMAN 8.00 X X 120000 0 0 LAURA ESSERMAN DIRECTOR, COFOUNDER 0.50 X 0 0 0 JEFFERY PFEFFER PHD DIRECTOR, COFOUNDER 0.50 X 0 0 0 ANNA BARKER PHD DIRECTOR 0.50 X 0 0 0 LUCAS DE BREED PHD MBA DIRECTOR 0.50 X 0 0 0 SUSAN FOLEY CFA DIRECTOR 0.50 X 0 0 0 MICHELE MARKUS DIRECTOR 0.50 X 0 0 0 ROBERT PATTERSON ESQ DIRECTOR 0.50 X 0 0 0 ROBYN LAWRIE RUTLEDGE MBA DIRECTOR 0.50 X 0 0 0 GREGORY C SIMON DIRECTOR 0.50 X 0 0 0 MARK SIMON MBA DIRECTOR 0.50 X 0 0 0 NMARCUS THYGESON MDMPH DIRECTOR 0.50 X 0 0 0 LAMBERT VAN DER WALDE MBA DIRECTOR 0.50 X 0 0 0 JAMES PALAZZOLO CEO 40.00 X 577025 0 57519 KATHRYN WATSON-FEINER VICE PRESIDENT OF FINANCE 40.00 X 400075 0 50655 ADAM ASARE CHIEF DATA OFFICER 40.00 X 255707 0 12839 IMOGENE MDUNN VICE PRESIDENT STATISTICS 40.00 X 341812 0 30395 RADHIKA SIVARAMAKRISHNA SR. VP, CLINICAL OPERATIONS 40.00 X 220140 0 31540 KARYN DIGIORGIO CHIEF COLLABORATION OFFICER 40.00 X 290720 0 40345 PAUL HENDERSON SR. DIRECTOR OF COLLABORATIONS 40.00 X 236971 0 46350 PHILIP BEINEKE DIRECTOR OF BIOMETRICS, ONCOLOGY 40.00 X 293318 0 52306 SARA HORTON EXECUTIVE DIRECTOR, DIVERSITY 40.00 X 291695 0 7648 SRIKRISHNA POSA SR SOFTWARE ENGINEER (THRU 10/23) 40.00 X 291431 0 9138 3318894 0 338735 66 0 1 0 REGENTS OF UC SAN FRANCISCO BOX 0897 1855 FOLSOM ST SUITE 425 SAN FRANCISCO CA 94143 CLINICAL RESEARCH 7612315 UNIVERSITY OF ALABAMA AT BIRMINGHAM - CO 1720 2ND AVENUE SOUTH AB 990 BIRMINGHAM AL 352940109 CLINICAL RESEARCH 2400175 UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE MC 0009 SAN DIEGO CA 920930009 CLINICAL RESEARCH 2189647 REGENTS OF THE UNIVERSITY OF MINNESOTA NW 5957 PO BOX 1450 MINNEAPOLIS MN 55485 CLINICAL RESEARCH 1234991 WAKE FOREST UNIVERSITY HEALTH SCIENCES MEDICAL CENTER BOULEVARD WINSTONSALEM NC 27157 CLINICAL RESEARCH 1014700 56 1389552 645302 1389552 CLINICAL TRIAL CONTRAC 541511 41729091 41729091 CONSULTING AND RESEARC 541511 334480 334480 42063571 1587428 1587428 54861046 54753698 107348 107348 107348 45147899 42063571 0 1694776 2040706 1296769 743937 13879772 12279197 1348573 252002 474768 409084 58029 7655 2138650 1881704 219626 37320 1061149 914338 129701 17110 109511 109511 268183 268183 20144 20144 2190326 2006920 143252 40154 419308 364242 47778 7288 95009 67221 25979 1809 3232348 2855727 345191 31430 355935 290389 58991 6555 255671 243849 8811 3011 173488 165466 5979 2043 11113 7817 3083 213 101152 81275 17965 1912 86553 73363 11948 1242 RESEARCH SITES 10491281 10440533 50748 PROGRAM MANAGEMENT 7977931 7977931 RESEARCH 2186878 2182990 3888 BAD DEBT EXPENSE 165000 165000 24566 17281 6814 471 47759442 43556096 3742383 460963 4269894 249898 4943974 5385955 1438761 279603 11320172 8639920 636230 725047 313825 200531 152663 113294 37862213 42672001 290041 136242 60913948 58201960 18472283 12880683 10935289 15030847 1463193 1463193 30870765 29374723 X 29720498 28638301 322685 188936 30043183 28827237 60913948 58201960 -2611543 1140528 255069 0 X 0 1 X 1 0 X 1876103 12652517 36277016 19517275 1389552 71712463 1876103 12652517 36277016 19517275 1389552 71712463 71712463 121682 87600 31363 517557 1587428 2345630 74058093 0.96830 0.98950 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 91220 91220 222605 200531 22074 113294 OTHER LONG TERM LIABILITIES 1463193 1463193 46288427 1140528 1140528 45147899 0 45147899 47759442 0 47759442 0 47759442 X X X X X 1 0 0 0 0 0 0 1 0 JAMES PALAZZOLO CEO 547025 0 30000 0 0 0 18022 0 39497 0 634544 0 0 0 KATHRYN WATSON-FEINER VICE PRESIDENT OF FINANCE 400075 0 0 0 0 0 11091 0 39564 0 450730 0 0 0 IMOGENE MDUNN VICE PRESIDENT STATISTICS 331812 0 10000 0 0 0 0 0 30395 0 372207 0 0 0 PHILIP BEINEKE DIRECTOR OF BIOMETRICS, ONCOLOGY 293318 0 0 0 0 0 11363 0 40943 0 345624 0 0 0 KARYN DIGIORGIO CHIEF COLLABORATION OFFICER 280720 0 10000 0 0 0 11223 0 29122 0 331065 0 0 0 SRIKRISHNA POSA SR SOFTWARE ENGINEER (THRU 10/23) 281431 0 10000 0 0 0 6710 0 2428 0 300569 0 0 0 SARA HORTON EXECUTIVE DIRECTOR, DIVERSITY 291695 0 0 0 0 0 5350 0 2298 0 299343 0 0 0 PAUL HENDERSON SR. DIRECTOR OF COLLABORATIONS 236971 0 0 0 0 0 5560 0 40790 0 283321 0 0 0 ADAM ASARE CHIEF DATA OFFICER 245707 0 10000 0 0 0 9776 0 3063 0 268546 0 0 0 RADHIKA SIVARAMAKRISHNA SR. VP, CLINICAL OPERATIONS 220140 0 0 0 0 0 6605 0 24935 0 251680 0 0 0 PART I, LINE 4A SRIKRISHNA POSA RECIEVED A SEVERANCE PAYMENT OF $62,790 PART I, LINE 7 DISCRETIONARY BONUSES ARE APPROVED BY THE BOARD OF DIRECTORS. DAVID MANDELKERN DIRECTOR 120000 MANAGEMENT ADVIOSRY SERVICES 0 X 1 645302 FMV 0 0 0 0 FORM 990, PART VI, SECTION B, LINE 11B FORM 990 IS PREPARED BY AN INDEPENDENT CPA FIRM IN CONJUNCTION WITH THE ORGANIZATION'S DIRECTOR OF FINANCE. A DRAFT OF FORM 990 IS REVIEWED BY THE DIRECTOR OF FINANCE, AND CORRECTIONS/MODIFICATIONS ARE MADE BY THE OUTSIDE CPA. THE REVISED DRAFT IS THEN REVIEWED BY THE DIRECTOR OF FINANCE. ANY CONCERNS ARE RAISED WITH THE CPA FIRM AND A CONSENSUS IS ACHIEVED. BOARD MEMBERS ARE SENT A COPY OF THE TAX RETURN PRIOR TO FILING FOR THEIR REVIEW. THE RETURN IS THEN FINALIZED AND ELECTRONICALLY FILED WITH THE TAXING AUTHORITIES. FORM 990, PART VI, SECTION B, LINE 12C THE CONFLICT OF INTEREST POLICY IS PRESENTED AND REVIEWED ANNUALLY. EACH BOARD MEMBER IS REQUIRED TO ACKNOWLEDGE IN WRITING THAT NO CONFLICT EXISTS. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION OF THE PRESIDENT OF THE ORGANIZATION WAS DETERMINED AND APPROVED BY VOTE OF THE BOARD OF DIRECTORS. PERSONNEL OF UCSF REVIEWED JOB REQUIREMENTS AGAINST TECHNICAL ABILITIES OF SUBCONTRACTORS AND DETERMINED WHETHER OR NOT THEY MATCHED. ALL SUBCONTRACTORS WERE ENGAGED AT BELOW-MARKET RATES. FORM 990, PART VI, SECTION C, LINE 19 ALL GOVERNING DOCUMENTS, AUDITED FINANCIAL STATEMENTS AND FORM 990, RETURN OF ORGANIZATION EXEMPT FROM INCOME TAX, ARE PROVIDED UPON WRITTEN REQUEST OR THROUGH THE QUANTUM LEAP HEALTHCARE COLLABORATIVE WEBSITE, AS WELL AS TO ANYONE WHO REQUESTS THEM IN WRITING. THEY ARE ALSO AVAILABLE FOR INSPECTION AT THE QLHC OFFICE DURING NORMAL BUSINESS HOURS.